Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 25/2/2021
SIETES contiene 93212 citas

 
 
<< anterior 21 a 40 de 265 siguiente >>
Presentar resultados
Seleccionar todas
21. Cita con resumen
Salat D, Llop R, Aguilera C, Danés I, Bosch M, Asensio C, Castañeda F, Esterlich E, Vallano A. Therapeutics enquiries about biological agents as a tool to identify safety aspects and patterns of use. European Journal of Hospital Pharmacy 2016;23:161-5. [Ref.ID 100163]
22. Cita con resumen
French JB, Bonacini M, Ghabril M, Foureau D, Bonkovsky HL. Hepatotoxicity associated with the use of anti-TNF-a agents. Drug Saf 2016;39:199-208. [Ref.ID 100140]
23.Enlace a cita original Cita con resumen
Vigario A. Pfizer despide a 30 altos cargos en España por incumplir el código ético. El Economista 2015:1. [Ref.ID 100040]
24. Cita con resumen
Yun H, Xie F, Delzell E, Levitan EB, Chen L, Lewis JD, Saag KG, Beukelman T, Winthrop KL, Baddley JW, Curtis JR. Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in Medicare. Arthritis Rheum 2016;68:56-66. [Ref.ID 99975]
26.Enlace a cita original Cita con resumen
Weber-Schoendorfer C, Oppermann M, Wacker E, Bernard N, on behalf of the network of French pharmacovigilance centres, Beghin D, Cuppers-Maarschalkerweerd B, Richardson JL, Rothuizen LE, Pistelli A, Malm H, Eleftheriou G, Kennedy D, Duman MK, Meister R, Schaefer C. Pregnancy outcome after TNF-a inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol 2015;80:727-39. [Ref.ID 99609]
27.
Boehncke W-H, Schön MP. Psoriasis. Lancet 2015;386:983-4. [Ref.ID 99530]
28. Cita con resumen
Anónimo. Apremilast for psoriasis and psoriatic arthritis. Drug Ther Bull 2015;53:105-8. [Ref.ID 99519]
29.Tiene citas relacionadas Cita con resumen
Bachelez H, Van de Kerkhof PCM, Strohal R, Kubanov A, Valenzuela F, Lee J-H, Yakusevich V, Chimenti S, Papacharalambous J, Proulx J, Gupta P, Tan H, Tawadrous M, Valdez H, Wolk R, OPT Compare Investigators. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet 2015;386:552-61. [Ref.ID 99491]
30.Tiene citas relacionadas Cita con resumen
Griffiths CEM, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp KU, UNCOVER-2, UNCOVER-3 investigators. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trial. Lancet 2015;386:541-51. [Ref.ID 99490]
31.Tiene citas relacionadas
Bachelez H. Interleukin-17 inhibition: a route to psoriasis clearance?. Lancet 2015;386:510-2. [Ref.ID 99489]
32. Cita con resumen
Anónimo. Consolidations de fracture retardées par des médicaments. Prescrire 2015;35:507-12. [Ref.ID 99440]
33. Cita con resumen
Anónimo. Drugs for psoriasis. Med Lett Drugs Ther 2015;57:81-4. [Ref.ID 99226]
34. Cita con resumen
Anónimo. Secukinumab (Cosentyx) for psoriasis. Med Lett Drugs Ther 2015;57:45-7. [Ref.ID 99209]
35. Cita con resumen
van Herwaarden N, van der Maas A, Minten MJM, van den hoogen FHJ, Kievit W, van Vollenhoven RF, Bijlsma JW, van den Bemt BJF, den Broeder AA. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. BMJ 2015;350:h1389. [Ref.ID 98963]
36. Cita con resumen
Scott DL, Ibrahim F, Farewell V, O'Keeffe AG, Walker D, Kelly C, Birrell F, Chakravarty K, Maddison P, Heslin M, Patel A, Kingsley GH. Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial. BMJ 2015;350:h1046. [Ref.ID 98857]
39.
Quirce S, Bobolea I, Barranco P. Asma: actualización terapéutica. Med Clin (Barc) 2014;142:317-22. [Ref.ID 97380]
40. Cita con resumen
Simon PC, Vallano A. Fármacos que inhiben el factor de necrosis tumoral alfa y embarazo. Med Clin (Barc) 2013;141:257-9. [Ref.ID 96078]
Seleccionar todas
 
<< anterior 21 a 40 de 265 siguiente >>